ClinicalTrials.gg
TerminatedNCT01190644Updated Nov 29, 2023Results posted

Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Participants With Solid Tumors

A Phase 2 interventional study of Sotatercept in Solid Tumors, sponsored by Merck Sharp & Dohme LLC. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-29.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Supportive care

Why this study was terminated
Isotope needed to conduct RBC/PV analysis (primary endpoint) no longer available from manufacturer. No alternatives available for use.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

What hematopoietic precursor compartments as well as hemoglobin subtypes are affected by dosing with sotatercept (ACE-011)? Based upon a similar prior study with Procrit, Celgene has determined that all of these goals could be obtained by an intense 10-patient sotatercept (ACE-011) pharmacodynamic study, completed by two well-known experts in the red cell production field.

02

Conditions studied

  • Solid Tumors

Keywords

  • Red Blood Cell Mass
  • Plasma Volume
  • Solid Tumors
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men and women ≥18 years of age.
  • confirmed diagnosis of a solid tumor documented by cytology or .
  • Presence of disease.
  • value between ≥8.0 to \<11.0 g/dL (≥80 to \<110 g/L).
  • ≥28 days must have elapsed (prior to pre-dose red blood cell mass / plasma volume test) since previous treatment with erythropoiesis-stimulating agent (including concurrent treatment with intravenous [IV] iron).
  • ≥28 days must have elapsed (prior to Day 1) since the last red blood cell transfusion and receipt of ≤2 units of blood in the past 56 days (prior to Day 1).
  • (ECOG) Performance status of 0 - 1.

Exclusion criteria

Exclusion Criteria:

At the time of screening, participants who have any grade ≥3 toxicity (according to the currently active minor version of v4.0) except for the following disease-related toxicities:

  • Hematological events - anemia, thrombocytopenia, neutropenia
  • Non-hematological events - nausea, vomiting, fatigue, muscle or bone/joint pain
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Sotatercept

    Participants will receive a single 35 mg dose of sotatercept by subcutaneous (SC) injection on Day 1, Day 43, and Day 85.

    Drug: Sotatercept

Interventions

  • single 35 mg SC dose of sotatercept on study Day 1, Day 43, and Day 85

    Also known as: ACE 011

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Red Blood Cell Mass Following a Single Dose of Sotatercept

    Blood samples were to be collected at baseline (Day 1, pre-dose) and at one timepoint between Day 14 and Day 28, and isotope dilution techniques used, to measure the change from baseline in red blood cell mass following a single dose of sotatercept.

    Time frame: Baseline (Day 1, pre-dose) and one timepoint between Day 14 and Day 28

Secondary outcomes

  1. Change From Baseline in Plasma Volume Following a Single Dose of Sotatercept

    Blood samples were collected at baseline (Day 1, pre-dose) and at one timepoint between Day 14 and Day 28, and isotope dilution techniques used, to measure the change from baseline in plasma volume following a single dose of sotatercept.

    Time frame: Baseline (Day 1, pre-dose) and one timepoint between Day 14 and Day 28

  2. Change From Baseline in Absolute Reticulocyte Count

    Blood samples were to be collected at baseline (Day 1, pre-dose) and at Day 211 to measure the change from baseline in absolute reticulocyte count.

    Time frame: Baseline (Day 1, pre-dose) and Day 211

  3. Change From Baseline in Erythropoietin Levels

    Blood samples were collected at baseline (Day 1, pre-dose) and at Day 211 to measure the change from baseline in erythropoietin levels.

    Time frame: Baseline (Day 1, pre-dose) and Day 211

  4. Change From Baseline in Hemoglobin Subtype A Following a Single Dose of Sotatercept

    Blood samples were collected at baseline (Day 1, pre-dose) and on Day 29, and hemoglobin electrophoresis used, to measure the change from baseline in hemoglobin subtype A following a single dose of sotatercept.

    Time frame: Baseline (Day 1, pre-dose) and Day 29

  5. Change From Baseline in Hemoglobin Subtype A2 Following a Single Dose of Sotatercept

    Blood samples were collected at baseline (Day 1, pre-dose) and on Day 29, and hemoglobin electrophoresis used, to measure the change from baseline in hemoglobin subtype A2 following a single dose of sotatercept.

    Time frame: Baseline (Day 1, pre-dose) and Day 29

  6. Change From Baseline in Hemoglobin Subtype C Following a Single Dose of Sotatercept

    Blood samples were collected at baseline (Day 1, pre-dose) and on Day 29, and hemoglobin electrophoresis used, to measure the change from baseline in hemoglobin subtype C following a single dose of sotatercept.

    Time frame: Baseline (Day 1, pre-dose) and Day 29

  7. Number of Participants Who Experienced One or More Adverse Events (AEs)

    An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.

    Time frame: Up to approximately 7 months

07

Results

Posted Nov 29, 2023

Participant flow

Participant flow — Overall Study
MilestoneSotatercept
Started5
Treated4
Completed2
Not completed3
Withdrew: Death2
Withdrew: Disease progression1

Outcome measures

PrimaryChange From Baseline in Red Blood Cell Mass Following a Single Dose of Sotatercept

Blood samples were to be collected at baseline (Day 1, pre-dose) and at one timepoint between Day 14 and Day 28, and isotope dilution techniques used, to measure the change from baseline in red blood cell mass following a single dose of sotatercept.

Time frame:
Baseline (Day 1, pre-dose) and one timepoint between Day 14 and Day 28

No measurements were reported for this outcome.

SecondaryChange From Baseline in Plasma Volume Following a Single Dose of Sotatercept

Blood samples were collected at baseline (Day 1, pre-dose) and at one timepoint between Day 14 and Day 28, and isotope dilution techniques used, to measure the change from baseline in plasma volume following a single dose of sotatercept.

Time frame:
Baseline (Day 1, pre-dose) and one timepoint between Day 14 and Day 28
Reported as:
Mean · mL
Change From Baseline in Plasma Volume Following a Single Dose of Sotatercept
mLSotatercept
Change From Baseline in Plasma Volume Following a Single Dose of Sotatercept-239.50 ± 219.91
SecondaryChange From Baseline in Absolute Reticulocyte Count

Blood samples were to be collected at baseline (Day 1, pre-dose) and at Day 211 to measure the change from baseline in absolute reticulocyte count.

Time frame:
Baseline (Day 1, pre-dose) and Day 211

No measurements were reported for this outcome.

SecondaryChange From Baseline in Erythropoietin Levels

Blood samples were collected at baseline (Day 1, pre-dose) and at Day 211 to measure the change from baseline in erythropoietin levels.

Time frame:
Baseline (Day 1, pre-dose) and Day 211
Reported as:
Mean · IU/L
Change From Baseline in Erythropoietin Levels
IU/LSotatercept
Change From Baseline in Erythropoietin Levels11.30 (11.3 to 11.3)
SecondaryChange From Baseline in Hemoglobin Subtype A Following a Single Dose of Sotatercept

Blood samples were collected at baseline (Day 1, pre-dose) and on Day 29, and hemoglobin electrophoresis used, to measure the change from baseline in hemoglobin subtype A following a single dose of sotatercept.

Time frame:
Baseline (Day 1, pre-dose) and Day 29
Reported as:
Mean · Percentage of hemoglobin subtype A
Change From Baseline in Hemoglobin Subtype A Following a Single Dose of Sotatercept
Percentage of hemoglobin subtype ASotatercept
Change From Baseline in Hemoglobin Subtype A Following a Single Dose of Sotatercept0.0 (0.0 to 0.0)
SecondaryChange From Baseline in Hemoglobin Subtype A2 Following a Single Dose of Sotatercept

Blood samples were collected at baseline (Day 1, pre-dose) and on Day 29, and hemoglobin electrophoresis used, to measure the change from baseline in hemoglobin subtype A2 following a single dose of sotatercept.

Time frame:
Baseline (Day 1, pre-dose) and Day 29
Reported as:
Mean · Percentage of hemoglobin subtype A2
Change From Baseline in Hemoglobin Subtype A2 Following a Single Dose of Sotatercept
Percentage of hemoglobin subtype A2Sotatercept
Change From Baseline in Hemoglobin Subtype A2 Following a Single Dose of Sotatercept0.0 (0.0 to 0.0)
SecondaryChange From Baseline in Hemoglobin Subtype C Following a Single Dose of Sotatercept

Blood samples were collected at baseline (Day 1, pre-dose) and on Day 29, and hemoglobin electrophoresis used, to measure the change from baseline in hemoglobin subtype C following a single dose of sotatercept.

Time frame:
Baseline (Day 1, pre-dose) and Day 29
Reported as:
Mean · Percentage of hemoglobin subtype C
Change From Baseline in Hemoglobin Subtype C Following a Single Dose of Sotatercept
Percentage of hemoglobin subtype CSotatercept
Change From Baseline in Hemoglobin Subtype C Following a Single Dose of Sotatercept0.0 (0.0 to 0.0)
SecondaryNumber of Participants Who Experienced One or More Adverse Events (AEs)

An AE is any untoward medical occurrence in a study participant administered a pharmaceutical product that does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not related to the medicinal product.

Time frame:
Up to approximately 7 months
Reported as:
Count of participants · Participants
Number of Participants Who Experienced One or More Adverse Events (AEs)
ParticipantsSotatercept
Number of Participants Who Experienced One or More Adverse Events (AEs)4

Adverse events

Collected over Up to approximately 7 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Sotatercept 35 mg2/5 (40%)3/4 (75%)4/4 (100%)
Most frequent serious events
Most frequent serious events
EventSotatercept 35 mg
CARDIO-RESPIRATORY ARRESTCardiac disorders1/4
CARDIOGENIC SHOCKCardiac disorders1/4
ABDOMINAL PAINGastrointestinal disorders1/4
PNEUMOPERITONEUMGastrointestinal disorders1/4
DEVICE DISLOCATIONGeneral disorders1/4
INFECTED SKIN ULCERInfections and infestations1/4
PROCEDURAL PAINInjury, poisoning and procedural complications1/4
DEHYDRATIONMetabolism and nutrition disorders1/4
HYPONATRAEMIAMetabolism and nutrition disorders1/4
Most frequent other events
Showing 10 of 30
Most frequent other events
EventSotatercept 35 mg
VOMITINGGastrointestinal disorders3/4
OEDEMA PERIPHERALGeneral disorders2/4
ANAEMIABlood and lymphatic system disorders1/4
THROMBOCYTOPENIABlood and lymphatic system disorders1/4
MYOCARDIAL INFARCTIONCardiac disorders1/4
ABDOMINAL DISTENSIONGastrointestinal disorders1/4
ASCITESGastrointestinal disorders1/4
CONSTIPATIONGastrointestinal disorders1/4
GASTROOESOPHAGEAL REFLUX DISEASEGastrointestinal disorders1/4
NAUSEAGastrointestinal disorders1/4

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Sotatercept
Mean63.8 ± 8.8
Sex: Female, Male
Sex: Female, Male(Participants)Sotatercept
Female3
Male2
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sotatercept
Hispanic or Latino0
Not Hispanic or Latino5
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sotatercept
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American3
White2
More than one race0
Unknown or Not Reported0
08

Study locations

3 sites
  • Saint Agnes Healthcare
    Baltimore, Maryland 21229, United States
  • Weinberg Cancer Institution at Franklin Square
    Baltimore, Maryland 21237, United States
  • Pennsylvania Oncology
    Philadelphia, Pennsylvania 19106, United States
09

References and documents

Publications

  • Cappellini MD, Porter J, Origa R, Forni GL, Voskaridou E, Galacteros F, Taher AT, Arlet JB, Ribeil JA, Garbowski M, Graziadei G, Brouzes C, Semeraro M, Laadem A, Miteva D, Zou J, Sung V, Zinger T, Attie KM, Hermine O. Sotatercept, a novel transforming growth factor beta ligand trap, improves anemia in beta-thalassemia: a phase II, open-label, dose-finding study. Haematologica. 2019 Mar;104(3):477-484. doi: 10.3324/haematol.2018.198887. Epub 2018 Oct 18. PubMed 30337358 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2010 to primary completion in Sep 2012, 27 months.

Results were first posted in Nov 2023, 11 years 2 months after primary completion. A results delay was requested in Jan 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2010
First posted
Aug 27, 2010
StartActual
Jun 1, 2010
Primary completionActual
Sep 18, 2012
CompletionActual
Oct 29, 2012
Results delay requested
Jan 30, 2014
Results first posted
Nov 29, 2023
Last update
Nov 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01190644
Responsible party
Sponsor
First posted
Aug 27, 2010
Start date
Jun 1, 2010
Primary completion
Sep 18, 2012
Completion
Oct 29, 2012
Results posted
Nov 29, 2023
Last update
Nov 29, 2023

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotatercept

Start the discussion